A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The discovery of endocannabinoid’s role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the efficacy of cannabis and its derivatives for psychiatric, neurodegenerative and movement disorders. A systematic search of randomized controlled trials of cannabis and its derivatives were conducted via databases (PubMed, Embase and the Cochrane Central Register of Controlled Trials). A total of 24 reports that evaluated the use of medical cannabis for Alzheimer’s disease, anorexia nervosa, anxiety, dementia, dystonia, Huntington’s disease, Parkinson’s disease, post-traumatic stress disorder (PTSD), psychosis and Tourette syndrome were included in this review. Trial quality was assessed with the Cochrane risk of bias tool. There is a lack of evidence on the therapeutic effects of cannabinoids for amyotrophic lateral sclerosis and dystonia. Although trials with positive findings were identified for anorexia nervosa, anxiety, PTSD, psychotic symptoms, agitation in Alzheimer’s disease and dementia, Huntington’s disease, and Tourette syndrome, and dyskinesia in Parkinson’s disease, definitive conclusion on its efficacy could not be drawn. Evaluation of these low-quality trials, as rated on the Cochrane risk of bias tools, was challenged by methodological issues such as inadequate description of allocation concealment, blinding and underpowered sample size. More adequately powered controlled trials that examine the long and short term efficacy, safety and tolerability of cannabis for medical use, and the mechanisms underpinning the therapeutic potential are warranted.
Abstract
The discovery of endocannabinoid’s role within the central nervous system and its potential therapeutic benefits have brought forth rising interest in the use of cannabis for medical purposes. The present review aimed to synthesize and evaluate the available evidences on the efficacy of cannabis and its derivatives for psychiatric, neurodegenerative and movement disorders. A systematic search of randomized controlled trials of cannabis and its derivatives were conducted via databases (PubMed, Embase and the Cochrane Central Register of Controlled Trials). A total of 24 reports that evaluated the use of medical cannabis for Alzheimer’s disease, anorexia nervosa, anxiety, dementia, dystonia, Huntington’s disease, Parkinson’s disease, post-traumatic stress disorder (PTSD), psychosis and Tourette syndrome were included in this review. Trial quality was assessed with the Cochrane risk of bias tool. There is a lack of evidence on the therapeutic effects of cannabinoids for amyotrophic lateral sclerosis and dystonia. Although trials with positive findings were identified for anorexia nervosa, anxiety, PTSD, psychotic symptoms, agitation in Alzheimer’s disease and dementia, Huntington’s disease, and Tourette syndrome, and dyskinesia in Parkinson’s disease, definitive conclusion on its efficacy could not be drawn. Evaluation of these low-quality trials, as rated on the Cochrane risk of bias tools, was challenged by methodological issues such as inadequate description of allocation concealment, blinding and underpowered sample size. More adequately powered controlled trials that examine the long and short term efficacy, safety and tolerability of cannabis for medical use, and the mechanisms underpinning the therapeutic potential are warranted.
참고문헌 (41)
- Pertwee RG, "Cannabinoid pharmacology: the first 66 years", Br J Pharmacol, 147(Suppl 1), pp.S163~S171 (2006)
- Koppel BS, "Systematic review : efficacy and safety of medical marijuana in selected neurologic disorders : report of the Guideline Development Subcommittee of the American Academy of Neurology", Neurology, 82, pp.1556~1563 (2014)
- Whiting PF, "Cannabinoids for medical use : A systematic review and meta-analysis", JAMA, 313, pp.2456~2473 (2015)
- Ujváry I, "Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy", Cannabis Cannabinoid Res, 1, pp.90~101 (2016)
- Klumpers LE, "Novel Δ(9)-tetrahydrocannabinol formulation NamisolⓇ has beneficial pharmacokinetics and promising pharmacodynamic effects", Br J Clin Pharmacol, 74, pp.42~53 (2012)
- Ahmed AI, "Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocannabinol in older persons with dementia", Psychopharmacology (Berl), 232, pp.2587~2595 (2015)
- Sagredo O, "Cannabinoids and neuroprotection in basal ganglia disorders", Mol Neurobiol, 36, pp.82~91 (2007)
- Kluger B, "The therapeutic potential of cannabinoids for movement disorders", Mov Disord, 30, pp.313~327 (2015)
- Leweke FM, "Therapeutic potential of Cannabinoids in psychosis", Biol Psychiatry, 79, pp.604~612 (2016)
- Rohleder C, "Cannabidiol as a potential new type of an antipsychotic. A critical review of the evidence", Front Pharmacol, 7, pp.422~ (2016)
- Iseger TA, "A systematic review of the antipsychotic properties of cannabidiol in humans", Schizophr Res, 162, pp.153~161 (2015)
- Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
- Gross H, "A double-blind trial of delta 9-tetrahydrocannabinol in primary anorexia nervosa", J Clin Psychopharmacol, 3, pp.165~171 (1983)
- Andries A, "Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial", Int J Eat Disord, 47, pp.18~23 (2014)
- Fabre LF, "The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety", J Clin Pharmacol, 21(8-9 Suppl), pp.377S~382S (1981)
- Glass RM, "Single-dose study of nabilone in anxious volunteers", J Clin Pharmacol, 21(8-9 Suppl), pp.383S~396S (1981)
- Zuardi AW, "Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects", Psychopharmacology(Berl), 76, pp.245~250 (1982)
- Bergamaschi MM, "Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients", Neuropsychopharmacology, 36, pp.1219~1226 (2011)
- Crippa JA, "Neural basis of anxiolytic effects of cannabidiol(CBD)in generalized social anxiety disorder : a preliminary report", J Psychopharmacol, 25, pp.121~130 (2011)
- Jetly R, "The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study", Psychoneuroendocrinology, 51, pp.585~588 (2015)
- Leweke FM, "Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia", Transl Psychiatry, 2, pp.e94~ (2012)
- Volicer L, "Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer’s disease", Int J Geriatr Psychiatry, 12, pp.913~919 (1997)
- Walther S, "Randomized, controlled crossover trial of dronabinol, 2.5mg, for agitation in 2 patients with dementia", J Clin Psychopharmacol, 31, pp.256~258 (2011)
- van den Elsen GA, "Tetrahydrocannabinol for neuropsychiatric symptoms in dementia : A randomized controlled trial", Neurology, 84, pp.2338~2346 (2015)
- van den Elsen GA, "Tetrahydrocannabinol in behavioral disturbances in dementia : A crossover randomized controlled trial", Am J Geriatr Psychiatry, 23, pp.1214~1224 (2015)
- Weber M, "Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial", J Neurol Neurosurg Psychiatry, 81, pp.1135~1140 (2010)
- Fox SH, "Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia", Mov Disord, 17, pp.145~149 (2002)
- Zadikoff C, "Cannabinoid, CB1 agonists in cervical dystonia:failure in a phase IIa randomized controlled trial", Basal Ganglia, 1, pp.91~95 (2011)
- Consroe P, "Controlled clinical trial of cannabidiol in Huntington’s disease", Pharmacol Biochem Behav, 40, pp.701~708 (1991)
- Curtis A, "A pilot study using nabilone for symptomatic treatment in Huntington’s disease", Mov Disord, 24, pp.2254~2259 (2009)
- López-Sendón Moreno JL, "A double-blind, randomized, cross-over, placebocontrolled, pilot trial with Sativex in Huntington’s disease", J Neurol, 263, pp.1390~1400 (2016)
- Sieradzan KA, "Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease : a pilot study", Neurology, 57, pp.2108~2111 (2001)
- Carroll CB, "Cannabis for dyskinesia in Parkinson disease : a randomized double-blind crossover study", Neurology, 63, pp.1245~1250 (2004)
- Chagas MH, "Effects of cannabidiol in the treatment of patients with Parkinson’s disease : an exploratory double-blind trial", J Psychopharmacol, 28, pp.1088~1098 (2014)
- Müller-Vahl KR, "Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol(THC) : a randomized crossover trial", Pharmacopsychiatry, 35, pp.57~61 (2002)
- Müller-Vahl KR, "Delta 9-tetrahydrocannabinol(THC)is effective in the treatment of tics in Tourette syndrome : a 6-week randomized trial", J Clin Psychiatry, 64, pp.459~465 (2003)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)
- Zuardi AW, "Cannabidiol monotherapy for treatmentresistant schizophrenia", J Psychopharmacol, 20, pp.683~686 (2006)
- Zuardi AW, "Antipsychotic effect of cannabidiol", J Clin Psychiatry, 56, pp.485~486 (1995)
- Bhattacharyya S, "Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology", Neuropsychopharmacology, 35, pp.764~774 (2010)
- Wang T, "Adverse effects of medical cannabinoids : a systematic review", CMAJ, 178, pp.1669~1678 (2008)